Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Oral opioid-induced constipation drugs present big opportunity for AstraZeneca

Wednesday, September 23rd, 2009

Earlier this week, AstraZeneca and Nektar Therapeutics signed a worldwide agreement for two development programs to address opioid-induced constipation for $125 million. NKTR-118 has completed a Phase II clinical trial and is being developed to treat constipation caused by the use of opioid pain products. NKTR-119, in preclinical development is ...

   
©2010 Canon Communications Pharmaceutical Media Group